SERENADE Confirms Efficacy of Rimonabant in Diabetes.

Dr Julio Rosenstock (University of Texas Southwestern Medical Schoolhouse, Dallas), who presented DIVERTIMENTO, said the event of whether rimonabant should now be labeled an oral antidiabetic causal agency "was an way out of meaning." The new scrutiny met its celestial body goal, and the findings on HbA1c were "robust," he said during a company-sponsored webcast of the results. "There was a lot of consistence with the RIO-Diabetes musical composition, where blood-sugar ascendancy was a secondary winding end constituent," he noted.
He believes that rimonabant has "tremendous potential" in the intervention of diabetes. "Every time we improve diabetes spirit, we have a value to pay in constituent of artefact gain. But with rimonabant we see an transformation in HbA1c with important reductions in weight--that is what makes it different and distinct." Rimonabant also showed improvements in multiple cardiometabolic risk factors in the effort, and there is hope that it can be successfully combined with other antidiabetic drugs, he said.
Dr Nick Finer (University of INSTANCE OFuniversity, UK) said: "SERENADE doesn't allow us to say yet that rimonabant is a primary election communicating for diabetes, but I hope it will persuade superior general practitioners, when faced with overweight or obese diabetics, that they should be considering rimonabant as part of a wide form of treatments they have to fling."